{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582195,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaad.2020.12.010","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T12:16:17Z","timestamp":1607429777000},"page":"1080-1091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis"],"prefix":"10.1016","volume":"86","author":[{"given":"Michael J.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Damsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M15-0729","article-title":"Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study","volume":"164","author":"Cleynen","year":"2016","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jaad.2020.12.010_bib4","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1007\/s10620-018-5096-2","article-title":"Stricturing and fistulizing Crohn's disease is associated with anti-tumor necrosis factor-induced psoriasis in patients with inflammatory bowel disease","volume":"63","author":"Weizman","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.jaad.2020.12.010_bib5","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2011.05.038","article-title":"Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010","volume":"67","author":"Shmidt","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.12.010_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.12.010_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/ced.12715","article-title":"Psoriatic alopecia","volume":"40","author":"George","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1346-8138.13762","article-title":"Cutaneous side-effects of biologics in immune-mediated disorders: a histopathological perspective","volume":"44","author":"Succaria","year":"2017","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib9","doi-asserted-by":"crossref","first-page":"e000314","DOI":"10.1136\/rmdopen-2016-000314","article-title":"Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA","volume":"3","author":"Jani","year":"2017","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.jaad.2020.12.010_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.jaad.2020.12.010_bib11","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.jaad.2020.12.010_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib13","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.jaad.2020.12.010_bib14","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/rheumatology\/keu214","article-title":"Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database","volume":"53","author":"Moulis","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.jaad.2020.12.010_bib15","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/rheumatology\/kex434","article-title":"Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far","volume":"57","author":"Jani","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.jaad.2020.12.010_bib16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/00365521.2019.1663260","article-title":"Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort","volume":"54","author":"Macaluso","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jgh3.12291","article-title":"Anti-TNF-induced lupus in patients with inflammatory bowel disease","volume":"4","author":"Picardo","year":"2020","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterized by interferon-gamma-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.jaad.2020.12.010_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/imj.12891","article-title":"Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors","volume":"45","author":"Subramaniam","year":"2015","journal-title":"Intern Med J"},{"issue":"9","key":"10.1016\/j.jaad.2020.12.010_bib20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/annrheumdis-2014-205318","article-title":"What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort","volume":"73","author":"Takase","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2008.12.008","article-title":"Anti-TNF alpha blockers, autoantibodies and autoimmune diseases","volume":"76","author":"Caramaschi","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"13","key":"10.1016\/j.jaad.2020.12.010_bib22","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1097\/01.MIB.0000435435.91988.b6","article-title":"The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies","volume":"19","author":"Yanai","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.jaad.2020.12.010_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","article-title":"Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases","volume":"48","author":"Daien","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib24","first-page":"378","article-title":"Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy?","volume":"11","author":"Decock","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","article-title":"New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication","volume":"42","author":"Tong","year":"2012","journal-title":"Intern Med J"},{"issue":"7","key":"10.1016\/j.jaad.2020.12.010_bib26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/1756-185X.12178","article-title":"Development of pulmonary and cardiac sarcoidosis during etanercept therapy","volume":"17","author":"Miyagi","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaad.2004.03.047","article-title":"Aggressive cutaneous T-cell lymphomas after TNF\u03b1 blockade","volume":"51","author":"Adams","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.12.010_bib28","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/ijd.14367","article-title":"Mycosis fungoides after treatment with tumor necrosis factor-alpha inhibitors for psoriasis: progression or onset?","volume":"58","author":"Partarrieu-Mejias","year":"2019","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/09546634.2010.534430","article-title":"Flare of pustular psoriasis after initiating ustekinumab therapy","volume":"23","author":"Wenk","year":"2012","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2020.12.010_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/ced.12392","article-title":"Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy","volume":"39","author":"Hay","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.12.010_bib31","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5021\/ad.2017.29.6.794","article-title":"Paradoxical flare of psoriasis after ustekinumab therapy","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1684\/ejd.2011.1164","article-title":"Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis","volume":"21","author":"Gregoriou","year":"2011","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib33","first-page":"202","article-title":"Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation","volume":"21","author":"Caca-Biljanovska","year":"2013","journal-title":"Acta Dermatovenerol Croat"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/1346-8138.13803","article-title":"Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy","volume":"45","author":"Suh","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.12.010_bib35","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.14309\/crj.2018.47","article-title":"Development of drug-induced inverse psoriasis in a patient with Crohn\u2019s disease","volume":"5","author":"Darwin","year":"2018","journal-title":"ACG Case Rep J"},{"issue":"9","key":"10.1016\/j.jaad.2020.12.010_bib36","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to\u00a0severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2340\/00015555-2871","article-title":"Eyelid dermatitis as a side effect of interleukin-17A inhibitors in psoriasis","volume":"98","author":"Teraki","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.12.010_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/CCID.S165605","article-title":"Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date","volume":"12","author":"Galluzzo","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib41","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/jdv.15156","article-title":"Paradoxical eczematous reaction to ixekizumab","volume":"33","author":"Munera-Campos","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib42","doi-asserted-by":"crossref","first-page":"e12751","DOI":"10.1111\/dth.12751","article-title":"Atopic-like dermatitis after secukinumab injection: a case report","volume":"32","author":"Burlando","year":"2019","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib43","article-title":"Secukinumab-induced pompholyx in a psoriasis patient","volume":"26","author":"Eichhoff","year":"2020","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2020.12.010_bib44","article-title":"Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report","volume":"8","author":"Bose","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.jaad.2020.12.010_bib45","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1016\/j.jaip.2020.06.064","article-title":"Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy","volume":"8","author":"Chicharro","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaad.2020.12.010_bib46","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1111\/jdv.16451","article-title":"Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis","volume":"34","author":"Hornick","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.12.010_bib47","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1111\/jdv.16416","article-title":"Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical sarcoidosis","volume":"34","author":"Wang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ced.13731","article-title":"Secukinumab-induced paradoxical pustular psoriasis","volume":"44","author":"Dogra","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.12.010_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2020.3702","article-title":"Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases","volume":"30","author":"M\u00f6ssner","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/03009742.2019.1594359","article-title":"New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report","volume":"49","author":"Currado","year":"2020","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib51","doi-asserted-by":"crossref","first-page":"e12505","DOI":"10.1111\/dth.12505","article-title":"Anti IL-17 flared psoriasis in a patient on secukinumab","volume":"30","author":"Noell","year":"2017","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jaad.2020.12.010_bib52","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jdcr.2019.09.005","article-title":"Eczematous eruption after guselkumab treatment for psoriasis","volume":"5","author":"Reyn","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib53","doi-asserted-by":"crossref","first-page":"e12954","DOI":"10.1111\/dth.12954","article-title":"Nummular dermatitis on guselkumab for palmoplantar psoriasis","volume":"32","author":"Truong","year":"2019","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14740338.2020.1736034","article-title":"A drug safety evaluation of risankizumab for psoriasis","volume":"19","author":"Huang","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16724","article-title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2020.12.010_bib57","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2020.12.010_bib58","doi-asserted-by":"crossref","first-page":"e13142","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2020.12.010_bib59","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.alit.2020.02.004","article-title":"An asthmatic case of psoriasiform eruption caused by administration of dupilumab","volume":"69","author":"Matsuda","year":"2020","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jdcr.2020.01.012","article-title":"Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis","volume":"6","author":"Varma","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/DER.0000000000000481","article-title":"Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis","volume":"30","author":"Fowler","year":"2019","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib62","first-page":"e7831","article-title":"Clinical psoriasiform dermatitis following dupilumab use for autoeczematization secondary to chronic stasis dermatitis","volume":"12","author":"Schrom","year":"2020","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.jaad.2020.12.010_bib63","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Zhu","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.12.010_bib64","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01676830.2018.1553190","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib65","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/DER.0000000000000357","article-title":"Patch testing in a patient on dupilumab","volume":"29","author":"Hoot","year":"2018","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2020.12.010_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/CCID.S123329","article-title":"Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis","volume":"11","author":"Awosika","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.12.010_bib67","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1111\/jdv.16218","article-title":"Drug-induced granulomatosis: is dupilumab the new kid on the block?","volume":"34","author":"Belhomme","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.12.010_bib68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/09546634.2019.1624683","article-title":"Rosacea associated with dupilumab therapy","volume":"32","author":"Heibel","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2020.12.010_bib69","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1111\/jdv.16094","article-title":"Inflammatory alopecia in patients on dupilumab: a retrospective cohort study at an academic institution","volume":"34","author":"Zhu","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.12.010_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jaad.2020.12.010_bib72","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part II: immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib73","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.immuni.2020.07.001","article-title":"High-dimensional T helper cell profiling reveals a broad diversity of stably committed effector states and uncovers interlineage relationships","volume":"53","author":"Tortola","year":"2020","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.jaad.2020.12.010_bib74","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.12.010_bib75","first-page":"73","article-title":"Psoriasis and inflammatory bowel disease: links and risks","volume":"6","author":"Vlachos","year":"2016","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"10.1016\/j.jaad.2020.12.010_bib76","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","article-title":"Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms","volume":"56","author":"Sherlock","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1016\/j.jaad.2020.12.010_bib77","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jaad.2020.12.010_bib78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2020.12.010_bib79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2475530318810851","article-title":"TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management","volume":"4","author":"Li","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"10.1016\/j.jaad.2020.12.010_bib80","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of\u00a0psoriasis with TNF-blockade therapy: a review\u00a0and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220331546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220331546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:13Z","timestamp":1759273273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220331546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0190962220331546"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.12.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}